Caroline Helwick

The plasma cell dyscrasia oral abstract session at the 2026 ASCO Annual Meeting featured several pivotal trials that advanced the field, including those highlighted here. Coverage of new treatments for amyloidosis will appear in a separate article. Mezigd... See more

Results of the phase III EMERALD-3 trial showed that combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE regimen, (single tremelimumab plus regular interval durvalumab ) with or without lenvatinib (oral multikinase VEGF an... See more

Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of trials are international studies investigating T-DXd as a p... See more

For years, the question of pregnancy after, or during treatment for, hormone receptor–positive breast cancer placed patients and their oncologists in an uncomfortable position. Endocrine therapy, prescribed for 5 years and increasingly for 10 years or lon... See more

Adding hormone therapy to postprostatectomy radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with very low prostate-specific antigen (PSA) levels before treatment. In the study, reported at the 2026 ASCO... See more